AIMS AND SCOPE

Psychiatry and Clinical Psychopharmacology (formerly Bulletin of Clinical Psychopharmacology 1996-2016) is an international, scientific, open access, online-only periodical published in accordance with independent, unbiased, and double-blinded peer-review principles. The journal is published quarterly in March, June, September, and December. The publication language of the journal is American English.

The aim of the journal is to bridge the gap between basic and clinical application by publishing high quality research in psychiatry and clinical psychopharmacology. The scope of the journal includes but not limited to psychiatry, child and adolescent psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences. Psychiatry and Clinical Psychopharmacology accepts research articles, reviews, case reports, letters to the editors, editorials, and short communications/brief reports.

The target audience of the journal includes specialists, residents, and scientists in psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related disciplines.

Psychiatry and Clinical Psychopharmacology is currently indexed in Science Citation Index Expanded, Scopus, Embase, HINARI, Proquest: Proquest Psychology Journals, Proquest Health&Medical Complete, PsychiNFO, PsycheSCAN: Psychopharmacology, EBSCO, and Chemical Abstracts (CAS).

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE), World Association of Medical Editors (WAME), Council of Science Editors (CSE), Committee on Publication Ethics (COPE), European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal is in conformity with the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).

Publication Fee Policy

Authors should pay a one-time article processing charge (APC) to cover the costs of peer review administration and management, production of articles in PDF and to other publishing functions. There are no surcharges based on the length of an article, figures or supplementary data. In order to cover publication costs, the standard APC for Psychiatry and Clinical Psychopharmacology is $590 (including taxes).

Please note that all submissions are evaluated by the Editorial Board and external reviewers in terms of scientific quality and ethical standards. APC payments have no effect on the outcome of the article’s evaluation and/or publication priority.

Account holder name: 26688848 - AVES Yayincilik Ltd. Shi.
Bank name: Halkbank/Gayrettepe
Account: 0850 53870964
IBAN no: TR19 0001 2009 8500 0053 8709 64

Advertisement Policy

Psychiatry and Clinical Psychopharmacology can publish advertisement images in the journal’s website upon the approval of the Editor in Chief. Potential advertisers should contact the Editorial Office. Advertisers have no effect on the editorial decisions or advertising policies.

Disclaimer

Statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the opinions of the editors, editorial board, and/or publisher; the editors, editorial board, and publisher disclaim any responsibility or liability for such materials.

Open Access Statement

Psychiatry and Clinical Psychopharmacology is an open access publication, and the journal’s publication model is based on Budapest Access Initiative (BOAI) declaration. All published content is available online, free of charge at www.psychiatry-psychopharmacology.com. The journal’s content is licensed under a Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International License which permits third parties to share and adapt the content for non-commercial purposes by giving the appropriate credit to the original work.

You can find the current version of the Instructions to Authors at: https://psychiatry-psychopharmacology.com/en/authors-106

Editor in Chief:
Mesut Cetin, M.D., Professor of Psychiatry
Address: Bagdat Caddesi Birgen Plaza 226/7 Kadikoy 34728 Istanbul, Turkey
Mobile & Whatsapp: +90-532-272-3252
pstkofarmakoloji@gmail.com

Publisher: AVES
Address: Büyükderece Cad., 105/9 34394 Şişli, İstanbul, Turkey
Phone: +90 212 217 17 00
E-mail address: info@avesyayincilik.com
www.avesyayincilik.com
CONTENTS

EDITORIAL

1  COP26 and health: Some progress, but too slow and not enough
Laurie Laybourn-Langton, Richard Smith

ORIGINAL ARTICLES

4  The Relationship of Plasma Transthyretin Level with Global or Regional Amyloid Beta Burden in Subjects with Amnestic Mild Cognitive Impairment: Cross-Sectional Amyloid PET Study
Kangyoon Lee, Young-Min Lee, Je-Min Park, Byung-Dae Lee, Eunsou Moon, Hee-jeong Jeong, Hwangyu Suh, Hak-Jin Kim, Kyongjune Pak, Kyung-Un Choi

9  Neuropsychological and Neurophysiological Assessment in Different Phases of Bipolar Disorder
Esra Kaymak Koca, Onur Durmaz, Saima Füsun Domaç, Sermin Kesebir

17  Pharmacokinetics and Effects on Saliva Flow of Sublingual and Oral Atropine in Clozapine-Treated and Healthy Adults: An Interventional Cross-Over Study
Omar Mubaslat, Michael Fitzpatrick, Andrew J. McLachlan, Tim Lambert

28  Pituitary Volume in Individuals with Social Anxiety Disorder
Mustafa Koç, Osman Mermi, Sabriye Aslan, Murad Atmaca

33  An Interpersonal Approach to the Treatment of Social Anxiety Disorder (Social Phobia): A Component Analysis
Ariel Stravynski, Lise Lachance

45  Turkish Version of the Psychosis Attachment Measure: A Reliability and Validity Analysis
Hüseyin Şehit Burhan, Yasir Şafak, Ayşe Göçer Gündoğmuş

54  Predictors of Caregiver Burden in Family Caregivers of Male Patients with Opioid Use Disorders
Mahmut Selçuk, Halil Ibrahim Oztürk, Hilal Uygur, Nalan Varsak, Suleyman Ozbek, Ibrahim Eren

63  The Silent Cry of Healthcare Workers: A Cross-Sectional Study on Levels and Determinants of Burnout among Healthcare Workers after First Year of the Pandemic in Turkey
Sevinç Ulusoy, Züla Çelik

72  COVID-19 Pandemic Psychosocial Impact Scale: Scale Development and Reliability and Validity Study
Ümmühan Deniz Sinanoğlu, Elif Yıyen

80  Differential Diagnosis Findings Between Alzheimer’s Disease and Major Depressive Disorder: A Review
Ricardo Silva dos Santos Durães, Juliana Emy Yokomizo, Fabiana Saffi, Cristiana Castanho de Almeida Roccia, Antonio de Pádua Serafim

CASE REPORTS

89  A Case of Neuroleptic Malignant Syndrome After COVID-19 Vaccination and Possible Mechanisms of Vaccines in the Formation of This Syndrome
İrem Taşçı, Kerim Uğur

93  Electroconvulsive Therapy in the Treatment of Catatonia Due To Systemic Lupus Erythematosus
Junier Gonçalves Júnior, Maria Eugenia Teixeira Bicalho, Lissiane Karine Noronha Guedes, Jose Gallucci-Neto, Rosa M.R. Pereira

LETTER TO THE EDITOR

96  Advance Healthcare Directives and Patients Afflicted with Dementia
Andrea Cioffi